BackgroundThe efficacy of current anticancer treatments is far from satisfactory and many patients still die of their disease. A general agreement exists on the urgency of developing molecularly targeted therapies. although their implementation in the clinical setting is in its infancy. In fact. https://www.hacklinkci.com/